FTD-17 (Frontotemporal Dementia with Parkinsonism Linked to Chromosome 17)

Introduction

Ftd 17 (Frontotemporal Dementia With Parkinsonism Linked To Chromosome 17) is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.

Overview

FTD-17, also known as Frontotemporal Dementia with Parkinsonism linked to Chromosome 17, is a rare hereditary neurodegenerative disorder characterized by progressive frontotemporal dementia and parkinsonian features. It is caused by mutations in the **MAPT**^{1Multi-modal dissection of cell-type specific TDP-43 pathology in the motor cortexPMID 41803120Open reference} (Microtubule-Associated Protein Tau) gene located on chromosome 17q21. FTD-17 represents one of the most common forms of inherited frontotemporal dementia and is classified within the tauopathies, a group of neurodegenerative diseases characterized by abnormal accumulation of tau protein in the brain.^{2Direct image-guided convective perfusion of the bilateral thalami for gene therapy in frontotemporal dementia: technical notePMID 41569880Open reference}

The disease typically manifests in mid-adulthood, with onset usually occurring between 35 and 55 years of age. FTD-17 follows an autosomal dominant inheritance pattern, meaning that a single copy of the mutated gene from an affected parent can cause the disease in offspring.^{3Trifluridine/Tipiracil Plus Bevacizumab Versus Regorafenib in Elderly Patients with Refractory Metastatic Colorectal Cancer: A Real-World Comparative StudyPMID 41827721Open reference}

Genetics and Molecular Basis

MAPT Gene Mutations

FTD-17 is caused by pathogenic mutations in the MAPT gene (also known as the tau gene), which provides instructions for making the tau protein. The MAPT gene is located on chromosome 17q21.31, a region that has been extensively studied due to its involvement in several neurodegenerative diseases.^{1Multi-modal dissection of cell-type specific TDP-43 pathology in the motor cortexPMID 41803120Open reference 4Morphological Changes in Femoral Trochlea After Extensor Realignment Surgery in Children With Congenital Patellar DislocationPMID 41783390Open reference}

Over 50 pathogenic MAPT mutations have been identified in patients with FTD-17 and related tauopathies. These mutations can be classified into several categories:^{4Morphological Changes in Femoral Trochlea After Extensor Realignment Surgery in Children With Congenital Patellar DislocationPMID 41783390Open reference 5Genetic Spectrum and Phenotypic Variability in Chinese Patients with Multisystem Proteinopathy and Related DisordersPMID 41737544Open reference}

1. Splice site mutations: Mutations that affect the alternative splicing of exon 10 in the MAPT gene, leading to an imbalance between 3-repeat (3R) and 4-repeat (4R) tau isoforms. Examples include the +16, +14, and intron 10 mutations.

2. Missense mutations: Point mutations that change single amino acids in the tau protein, altering its ability to bind to microtubules and promoting aggregation. Common examples include P301L, P301S, G272V, and R406W.^{5Genetic Spectrum and Phenotypic Variability in Chinese Patients with Multisystem Proteinopathy and Related DisordersPMID 41737544Open reference}

3. Exonic mutations: Mutations within exons that affect tau protein structure and function.

The most frequently observed mutation in FTD-17 is the P301L mutation, which has been identified in numerous families worldwide and is associated with a relatively early onset and rapid progression.[^6] [^6]

Tau Protein Dysfunction

The tau protein plays a critical role in maintaining the structure and function of neurons. In FTD-17, pathogenic MAPT mutations lead to:^{2Direct image-guided convective perfusion of the bilateral thalami for gene therapy in frontotemporal dementia: technical notePMID 41569880Open reference} [^7]

• Hyperphosphorylation: Abnormal phosphorylation of tau protein reduces its ability to bind to microtubules, leading to microtubule destabilization and impaired axonal transport.

• Aggregation: Mutant tau proteins have an increased tendency to form insoluble aggregates, including neurofibrillary tangles (NFTs), which are hallmark pathological features of FTD-17.[^7]

• Tau isoform imbalance: Mutations affecting exon 10 splicing lead to an imbalance between 3R and 4R tau isoforms, disrupting normal tau function.

Clinical Features

Core Symptoms

FTD-17 presents with a combination of frontotemporal dementia symptoms and parkinsonian features:^{3Trifluridine/Tipiracil Plus Bevacizumab Versus Regorafenib in Elderly Patients with Refractory Metastatic Colorectal Cancer: A Real-World Comparative StudyPMID 41827721Open reference} [^8]

1. Frontotemporal Dementia Symptoms:

   • Progressive changes in personality and behavior

   • Disinhibition and inappropriate social conduct

   • Apathy and loss of initiative

   • Language difficulties, including progressive aphasia

   • Impaired judgment and executive function

   • Memory impairment (typically less prominent than in Alzheimer’s disease)

2. Parkinsonian Features:

   • Bradykinesia (slowness of movement)

   • Muscle rigidity

   • Tremor (less common)

   • Gait disturbance and postural instability

   • Mask-like facial expression

Disease Progression

FTD-17 typically follows a progressive course over 5-15 years:[^8] [^9]

• Early stage: Behavioral changes and mild cognitive impairment

• Middle stage: Progressive dementia, motor symptoms become more prominent

• Late stage: Severe cognitive decline, complete motor impairment, and eventual death

Neuropathology

Key Pathological Features

Post-mortem examination of FTD-17 brains reveals characteristic neuropathological changes:[^7] [^10]

1. Neurofibrillary Tangles (NFTs): Abundant NFTs composed of hyperphosphorylated tau protein are observed in neurons throughout the brain, particularly in the frontal and temporal lobes, basal ganglia, and brainstem.

2. Tau-positive Inclusions: Various tau-positive inclusions are seen, including:

   • Pick bodies (in Pick disease variant)

   • Globose neurofibrillary tangles

   • Thorn-shaped astrocytes

   • Coiled bodies in oligodendrocytes

3. Neuronal Loss and Atrophy: Significant neuronal loss is observed in the frontal and temporal cortices, with corresponding brain atrophy that may be evident on neuroimaging.

4. Gliosis: Reactive astrocytosis and microglial activation are present in affected brain regions.

Diagnosis

Clinical Diagnosis

FTD-17 diagnosis is based on:^{2Direct image-guided convective perfusion of the bilateral thalami for gene therapy in frontotemporal dementia: technical notePMID 41569880Open reference}0

1. Clinical evaluation: Assessment of cognitive, behavioral, and motor symptoms

2. Family history: Identification of affected family members (autosomal dominant pattern)

3. Neuropsychological testing: Comprehensive assessment of cognitive function

4. Neuroimaging: MRI and PET scans to detect frontotemporal atrophy and hypometabolism

Genetic Testing

Genetic testing for MAPT mutations is available and can confirm the diagnosis:[^9]

• Confirmatory genetic testing: Identification of pathogenic MAPT mutations

• Presymptomatic testing: Available for at-risk individuals in affected families

• Genetic counseling: Recommended for families considering testing

Differential Diagnosis

FTD-17 must be distinguished from:

• Other forms of frontotemporal dementia (bvFTD, semantic dementia, progressive nonfluent aphasia)

• Parkinson’s disease

• Progressive supranuclear palsy

• Corticobasal degeneration

• Alzheimer’s disease

Treatment and Management

Current Treatment Options

No disease-modifying therapies are available for FTD-17. Management focuses on symptomatic treatment and supportive care:[^10]

1. Pharmacological treatments:

   • SSRIs: For behavioral symptoms (sertraline, fluoxetine)

   • Antipsychotics: For severe behavioral disturbances (risperidone, olanzapine)

   • Cholinesterase inhibitors: May provide modest benefit in some patients

   • Levodopa: For parkinsonian features (limited efficacy)

2. Non-pharmacological interventions:

   • Behavioral and environmental modifications

   • Speech and language therapy

   • Physical therapy

   • Occupational therapy

   • Nutritional support

Emerging Therapies

Several therapeutic approaches are under investigation:[^10]

• Tau-targeted therapies: Immunotherapies targeting tau protein (e.g., semorinemab, tilavonemab)

• Small molecule inhibitors: Compounds that inhibit tau aggregation

• Gene therapy: Approaches targeting MAPT gene expression

• Microtubule stabilizers: Drugs that compensate for tau dysfunction

Epidemiology

FTD-17 is rare, accounting for approximately 3-5% of all frontotemporal dementia cases:^{2Direct image-guided convective perfusion of the bilateral thalami for gene therapy in frontotemporal dementia: technical notePMID 41569880Open reference}1

• Prevalence: Estimated at 1-2 per 100,000 population

• Age of onset: Typically 35-55 years

• Disease duration: 5-15 years from symptom onset

• Inheritance: Autosomal dominant

Research Directions

Current Research Focus

1. Biomarker development: Identifying reliable biomarkers for early diagnosis and disease monitoring

2. Tau propagation: Understanding how tau pathology spreads in the brain

3. Genetic modifiers: Identifying factors that modify disease severity and age of onset

4. Clinical trials: Testing disease-modifying therapies in clinical trials

Key Research Institutions

• University of Pennsylvania FTD Center

• UCL Institute of Neurology

• Mayo Clinic

• University of California, San Francisco Memory and Aging Center

See Also

• Frontotemporal Dementia

• Tauopathies

• MAPT Gene

• Progressive Supranuclear Palsy

• Corticobasal Degeneration

• Tau Protein

Background

The study of Ftd 17 (Frontotemporal Dementia With Parkinsonism Linked To Chromosome 17) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• Multi-modal dissection of cell-type specific TDP-43 pathology in the motor cortex. (2026 Mar 9) - Nature communications

• Direct image-guided convective perfusion of the bilateral thalami for gene therapy in frontotemporal dementia: technical note. (2026 Mar 1) - Journal of neurosurgery

• Trifluridine/Tipiracil Plus Bevacizumab Versus Regorafenib in Elderly Patients with Refractory Metastatic Colorectal Cancer: A Real-World Comparative Study. (2026 Feb 28) - Cancers

• Morphological Changes in Femoral Trochlea After Extensor Realignment Surgery in Children With Congenital Patellar Dislocation. (2026 Feb) - Orthopaedic journal of sports medicine

• Genetic Spectrum and Phenotypic Variability in Chinese Patients with Multisystem Proteinopathy and Related Disorders. (2026) - Degenerative neurological and neuromuscular disease

External Links

• [MAPT Gene - Gen- Frontotemporal Dementia - NINDS](https://www.ninds.nih.gov/Disorder- The Association for Frontotemporal Degeneration